Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278874

—

b5380af6-d55f-5b8c-98ca-3f83e67dea2e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.640
  • INTERFERON_GAMMA_RESPONSE+0.550
  • IL6_JAK_STAT3_SIGNALING+0.470
  • TNFA_SIGNALING_VIA_NFKB+0.470
  • ALLOGRAFT_REJECTION+0.420
  • INFLAMMATORY_RESPONSE+0.420
  • COMPLEMENT+0.300
  • IL2_STAT5_SIGNALING+0.290
  • G2M_CHECKPOINT+0.280
  • APICAL_JUNCTION+0.260

Top 10 suppressed

  • ANGIOGENESIS-0.290
  • MYOGENESIS-0.240
  • BILE_ACID_METABOLISM-0.200
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
  • OXIDATIVE_PHOSPHORYLATION-0.170
  • FATTY_ACID_METABOLISM-0.140
  • PEROXISOME-0.140
  • PANCREAS_BETA_CELLS-0.130
  • DNA_REPAIR-0.110
  • NOTCH_SIGNALING-0.110

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ERR2278877
head-neck@1
——0.873
2MNG766
mng-umap@100
——0.861
3TCGA-AR-A1AT-01A-11R-A12P-07
breast-umap@18
—C0.848
48ed1ae0f-90db-445c-9805-f8ae9b55da80
melanoma-umap@29
——0.845
520080189.TNBC
breast-umap@18
—E0.845
6TCGA-XF-A8HE-01A-11R-A36F-07
bladder-landscape@3
——0.843
7SRR27320692
colon-landscapes@1
——0.842
8SRR8943003
bladder-landscape@3
——0.842
9BSR_16_0031_E2_S98
breast-umap@18
—C0.836
10s0112313
melanoma-umap@29
——0.827

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.640Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.550Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.470Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.470Inavolisib— uncovered
ALLOGRAFT_REJECTION0.420Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.420Idelalisib— uncovered
COMPLEMENT0.300Inavolisib— uncovered
IL2_STAT5_SIGNALING0.290Idelalisib— uncovered
G2M_CHECKPOINT0.280Inavolisib— uncovered
APICAL_JUNCTION0.260Inavolisib— uncovered
MYC_TARGETS_V20.250Idelalisib— uncovered
MYC_TARGETS_V10.230Inavolisib— uncovered
MITOTIC_SPINDLE0.210Inavolisib— uncovered
KRAS_SIGNALING_UP0.190Inavolisib— uncovered
APOPTOSIS0.180Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.180Inavolisib— uncovered
P53_PATHWAY0.170Idelalisib— uncovered
HYPOXIA0.150Idelalisib— uncovered
UV_RESPONSE_UP0.150Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.140Idelalisib— uncovered